This online E-Forum is supported by independent educational grants from Novo Nordisk US, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
The management of cardiovascular risk in patients with type 2 diabetes continues to evolve with changing guidelines and emerging data. This online e-forum will provide the most frequently asked questions and answers from education on the evidence-based recommendations for management of cardiovascular risk in patients with type 2 diabetes. It will also provide the latest data on the long-term cardiovascular outcomes associated with the newest medications to treat type 2 diabetes, including incretin therapies and sodium glucose transporter-2 inhibitors. Participants will also have access to an online lecture that provides baseline information on these topics. For three months, participants can submit additional questions and the expert faculty will post new answers weekly.
The target audience for this educational activity is endocrinologists, cardiologists, primary care clinicians, and other healthcare providers who treat patients and are interested in the primary prevention of cardiovascular disease in patients with diabetes.
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Harold Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director and President,
Louisville Metabolic and Atherosclerosis Research Center
Dr. Bays has received research grants from: Amarin Corporation, Amgen, Ardea Biosciences, Arisaph Pharmaceuticals, AstraZeneca, Bristol-Meyers Squibb, Catabasis Pharmaceuticals, CymaBayTherapeutics, Eisai, Elcelyx Therapeutics, Eli Lilly and Company, Esperion Therapeutics, Ferrer/Chiltern International, Gilead Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Hisun USA, Home Access Health Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Kowa American Corporation, Merck & Co., Necktar, Novartis, Novo Nordisk, Omthera Pharmaceuticals, Orexigen Therapeutics, Pfizer, ProNova Solutions, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda Pharmaceuticals U.S.A., and TimPharma LLC. He has consulted for: Alnylam Pharmaceuticals, Akcea Therapeutics, Amgen, AstraZeneca, Eli Lilly and Company, Ionis Pharmaceuticals (ISIS), Janssen Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Moderna Therapeutics, Novartis, Procter & Gamble, ProNova Solutions, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A. He has also been a speaker for: Amarin Corporation, Amgen, AstraZeneca, Eisai, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A.
Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA
Dr. Blonde has consulted for: AstraZeneca, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. He has been a part of the speaker’s bureau for: AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk, and Sanofi. He has received grant and research support from: AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi.
Yehuda Handelsman, MD, FACP, FACE, FNLA
Medical Director and Principal Investigator,
Metabolic Institute of America
Dr. Handelsman has received research grants from: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Esperion, Grifols, Hanmi Pharmaceutical, Intarcia Therapeutics, Inc., GlaxoSmithKline, Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi. He has consulted for: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Novo Nordisk, Regeneron Pharmaceuticals, Inc., and Sanofi. He has been a part of the speaker’s bureau for: Amarin Corporation, Amgen, AstraZeneca, Boehringer Ingelheim-Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Regeneron Pharmaceuticals, Inc., and Sanofi. He was the IP President of the American College of Endrocrinology. He was the editor of the Journal of Diabetes.
Accredited Provider Disclosure
Christine Tebben and Stephanie Breslan, MS, of Forefront Collaborative have no financial relationships to disclose relative to the content of this CME activity.
Disclosure of Unlabeled Use
This educational activity includes discussion of off-label uses of drugs.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please review the activity materials and respond to the post-test and evaluation. You will receive a digital copy of your credit certificate once you have successfully completed this program. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.